Xcout Intel
Muna Therapeutics
Muna Therapeutics is a privately held biopharmaceutical company founded in 2020 with headquarters in Copenhagen, Denmark, and operations in Leuven. The company discovers and develops novel therapies aimed at slowing or stopping devastating neurodegenerative diseases like Alzheimer's and Parkinson's.
Subscribe to see Muna Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Muna Therapeutics at a glance
Muna Therapeutics is a biotechnology company headquartered in Denmark. Its most recent funding round, Series A, raised $73M in July 2021. Xcout tracks 9 named people at Muna Therapeutics, including Michel Detheux (Chief Executive Officer & Board Director).
Muna Therapeutics leadership
- Michel DetheuxChief Executive Officer & Board Director
- LUC DOCHEZDroia Ventures
- Donald NicholsonIndependent Chair
- Rita Balice-GordonIndependent Director
- Camilla HansenNovo Holdings
- Cillian KingEQT
3 more named people on record for Muna Therapeutics, with roles, board committees and tenure — see the full roster →
Muna Therapeutics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $73M | 10 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Muna Therapeutics competitors
A few of Muna Therapeutics's closest competitors — see the full list of competitors and alternatives →
Neumirna Therapeutics is a biotechnology company founded in 2021 and headquartered in Copenhagen, Denmark. The firm is dedicated to pioneering RNA-based therapies to treat epilepsy, Parkinson's disease, and other neurological disorders.
CuraSen Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapies to treat neurodegenerative diseases by targeting specific receptor systems in the brain. The company's scientific approach focuses on restoring neurovascular and neuronal function to serve patients suffering from conditions such as Parkinson's disease and other neurodegenerative disorders.
FoldLogic Bio is a clinical-stage biotechnology company developing targeted immunotherapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Multiple System Atrophy. The company focuses on modulating the central nervous system's immune responses, specifically targeting microglial activity, alpha-synuclein, and TREM2 to halt disease progression.
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases, including neuropsychiatric and neurodegenerative disorders. It uses neuroscience, data science, and biomarkers to identify and advance treatments for patients with these conditions.
Arkuda Therapeutics is a biotechnology company developing small-molecule treatments for neurodegenerative diseases, with a focus on restoring lysosomal function and addressing progranulin-related disease biology. Its programs are aimed particularly at patients with frontotemporal dementia and other disorders involving lysosomal dysfunction.
BioArctic AB is a Swedish biopharmaceutical company developing disease-modifying treatments for neurodegenerative disorders, particularly Alzheimer’s and Parkinson’s disease. It serves patients and healthcare systems through its own drug-development programs and partnerships with pharmaceutical companies, including Eisai.
Get Muna Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Muna Therapeutics in Xcout Intel
- 9 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access